Summary
This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation
study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of
ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies
Part 1 of the study is monotherapy dose escalation. Closed November 2020 Part 2 of the study
is monotherapy expansion groups for relapsed/refractory chronic lymphocytic leukaemia (CLL),
AML/ myelodysplastic syndromes (MDS), and multiple myeloma (MM). Closed November 2020 Part 3
is a sequential, dose-escalation study of the combination of AZD5991 and venetoclax in
subjects with relapsed/refractory AML